Preventing Alzheimer’s Disease

  title={Preventing Alzheimer’s Disease},
  author={M. Sano and H. Grossman and K. Dyk},
  journal={CNS Drugs},
  • M. Sano, H. Grossman, K. Dyk
  • Published 2008
  • Medicine
  • CNS Drugs
  • Alzheimer’s disease is an ever-increasing health concern among the aging population, and as we research new and existing treatments for this disease we begin to uncover possibilities for its prevention. Observational studies and animal models have provided promising findings and generated excitement, but placebo-controlled clinical trials are required to demonstrate true efficacy for these treatments.In the past two decades, clinical trials have led to the approval of symptomatic treatments for… CONTINUE READING
    146 Citations
    Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease
    • 72
    Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
    • 111
    • PDF
    Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies
    • 13
    • PDF
    Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease
    • 18
    Alzheimer's disease immunization strategies : a review of current research
    • Highly Influenced
    Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease
    • 260
    How does brain insulin resistance develop in Alzheimer's disease?
    • 219
    • PDF


    Disease-modifying therapies for Alzheimer disease
    • 232
    Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease
    • 114
    • PDF
    Neuroinflammatory perspectives on the two faces of Alzheimer’s disease
    • 162
    Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease
    • 115